Search Results for: asterias

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte

February 1, 2021 / By / 2 Comments
VC-01-post-implant-final1-e1503703572933, viacyte

It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a …

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte Read More »

Asterias interview: stem cell spinal cord injury trials advance

February 1, 2021 / By
Asterias

Recently I had the opportunity to talk with the leadership of Asterias, a California biotech doing exciting clinical research using stem cells as the basis for treatment of spinal cord injury. The interview covers the past (Geron patients), present, and future. I spoke with Asterias President and CEO Stephen Cartt and CMO Edward Wirth. How …

Asterias interview: stem cell spinal cord injury trials advance Read More »

Early, but encouraging data from Asterias on stem cells for spinal cord injury

February 1, 2021 / By
Asterias

As I posted recently, Asterias Biotherapeutics has had good early safety results so far in its historic stem cell trial for spinal cord injury and now the company presented some early, encouraging hints at efficacy.  However, a caveat here is that this is not an RCT (randomized controlled trial). Ed Wirth, CMO of Asterias, presented the …

Early, but encouraging data from Asterias on stem cells for spinal cord injury Read More »

Stem cell good news as Asterias SCI trial to expand with strong safety data

February 1, 2021 / By / 9 Comments
Jake-Javier-CIRM-Photo

The stem cell clinic trial being run by Asterias Biotherapeutics for spinal cord injury (SCI) reported (via CIRM) some preliminary very good news as it is so far seems safe and will be expanded to involve more patients. In the next phase, reportedly “Asterias is now looking to enroll 5-8 patients for this 20 million …

Stem cell good news as Asterias SCI trial to expand with strong safety data Read More »

Stem cell good news briefs: TiGenix, Asterias, CIRM, Awards, & More

December 22, 2023 / By / 4 Comments
TiGenix

There’s a growing stream of stem cell good news of late. Stem cell biotech, TiGenix, reported encouraging Phase 3 allogeneic results on stem cells. A big milestone. I can’t wait to see the actual data. Its product, Cx601, has so far been safe and effective for perianal fistulas in Crohn’s disease. See more from Alexey on this. CIRM has funded the largest …

Stem cell good news briefs: TiGenix, Asterias, CIRM, Awards, & More Read More »

Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial

February 1, 2021 / By / 1 Comment
jane-lebkowski

The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung …

Interview with Jane Lebkowski on Asterias FDA-approved Stem Cell Trial Read More »

TGIF stem cell headlines of week: Asterias, lasers, immunity, & more

February 1, 2021 / By
Laser-tooth-stem-cells

It’s been an important week for stem cells. Although I’ve been busy working on multiple grants and papers, when I take a break I like to read up on what’s been going on with stem cells. What are the top stem cell stories and headlines of the week? CIRM awarded Asterias (a subsidiary of BioTime) …

TGIF stem cell headlines of week: Asterias, lasers, immunity, & more Read More »

Great news: BioTime Subsidiary Asterias Acquires Geron Embryonic Stem Cell Program

February 1, 2021 / By / 1 Comment

BioTime (BTX), via its subsidiary Asterias, has formally purchased the Geron (GERN) embryonic stem cell (ESC) research program and assets. Incidentally, Asterias in nature refers to a genus of sea stars including starfish and you can see it in their logo. Perhaps this was chosen given the amazing regenerative capacity of starfish? You may recall …

Great news: BioTime Subsidiary Asterias Acquires Geron Embryonic Stem Cell Program Read More »

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36

August 23, 2022 / By / 2 Comments
Peter-Marks-Regenerative-Medicine-Advanced-Therapy-Designation-RMAT-

This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the last month. I’m assuming for the purposes of this resource page that all self-reports are accurate. Note that the links embedded into the firm …

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36 Read More »

7-Year Glitch? Updates on my overly optimistic 2013 stem cell predictions for 2020

February 1, 2021 / By / 3 Comments
STEM-CELL-PREDICTIONS

Back in 2013, a half dozen years ago, I went out on a limb and made predictions for the stem cell field for 2020. These are different than my yearly predictions for the coming year (for instance, you can see my predictions made in 2018 for this year of 2019 here). As to my 2013 …

7-Year Glitch? Updates on my overly optimistic 2013 stem cell predictions for 2020 Read More »